[Asia Economy Reporter Ji Yeon-jin]
▲HanAll Biopharma = Submission of clinical trial protocol for Phase 3 clinical trial in Japan for HL161 (generic name Batoclimab), an antibody drug for autoimmune disease treatment, targeting myasthenia gravis
▲AK Holdings = Regarding reports on the issuance of exchangeable bonds, various options are being reviewed, but nothing has been finalized yet.
▲Jeju Air = Regarding reports on the shareholder allocation rights offering, various measures to improve financial structure are being reviewed, but nothing has been specifically decided yet.
▲Hanwha General Insurance = Decision to proceed with a third-party allotment rights offering worth 175 billion KRW
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
